Transcatheter aortic valve replacement (TAVR) is an established treatment for severe,
symptomatic, aortic stenosis (AS) in patients of all risk categories and now comprises 12.5 …

Cardiac amyloidosis is caused by the extracellular deposition of amyloid fibrils in the heart,
involving not only the myocardium but also any cardiovascular structure. Indeed, this …

Background Studies assessing the differential impact of sex on outcomes of aortic valve
replacement (AVR) yielded conflicting results. We sought to investigate sex‐related …

Aortic stenosis (AS) affects about 1.5 million people in the United States and is associated
with a 5-year survival rate of 20% if untreated. In these patients, aortic valve replacement is …

Background and aims Activated innate immune cells infiltrating the valve and their secreted
cytokines drive the differentiation of valve interstitial cells into myofibroblastic and …

Abstract The UK Biobank (UKB) is a health research resource of major international
importance, incorporating comprehensive characterization of> 500 000 men and women …

Calcific aortic stenosis is a progressive disease that has become more prevalent in recent
decades. Despite advances in research to uncover underlying biomechanisms, and …

Risk prediction of future atherothrombotic cardiovascular events is currently based on
conventional risk factor assessment and the use of validated algorithms, such as the …

Despite the increasing popularity of Transcatheter aortic valve implantation (TAVI) in
patients with high surgical risk, there is no current guideline for the management of patients …

Our perspectives on aortic stenosis (AS) are changing. Evolving from the traditional thought
of a passive degenerative disease, developing a greater understanding of the condition's …